Celltrion¡¯s Covid-19 cure passes committee scrutiny; launch expected early Feb.
이 글자크기로 변경됩니다.
(예시) 가장 빠른 뉴스가 있고 다양한 정보, 쌍방향 소통이 숨쉬는 다음뉴스를 만나보세요. 다음뉴스는 국내외 주요이슈와 실시간 속보, 문화생활 및 다양한 분야의 뉴스를 입체적으로 전달하고 있습니다.
The committee said Rekirona can be used for patients based on the safety and efficacy data submitted, and regulatory approval can be granted subject to submission of Phase 3 trial results later. However, the committee limited target patients to those with moderate symptoms and only high-risk patients with mild symptoms.
The therapy developed by Celltrion is now pending at the Final Review Committee, which is just customary, suggesting that all necessary procedures for approval virtually came to an end, industry sources said.
The latest triumph came after an ad hoc expert panel of the Ministry of Food and Drug Safety recommended marketing approval early last week on condition of a Phase 3 clinical trial.
As a result, Rekirona is expected to be in clinical practice to treat Covid-19 patients ahead of the upcoming Lunar New Year holiday.
During a Monday briefing, Food and Drug Safety Minister Kim Gang-lip said regulatory approval of the treatment is expected to be completed in early February unless there are problems with all review procedures.
Celltrion already finished initial production of Rekirona to cover up to 100,000 patients. The company plans to add Rekirona products for up to 3 million people within this year. Whether the therapy can be offered for free in Korea remains undetermined.
Celltrion shares closed Thursday 1.7 percent higher at 334,500 won ($299.06), extending gains for the fourth day in a row. Its affiliates Celltrion Pharm and Celltrion Healthcare finished 3.7 percent lower at 186,600 won and 2.23 percent lower at 149,200 won, respectively.
[¨Ï Maeil Business Newspaper & mk.co.kr, All rights reserved]
Copyright © 매일경제 & mk.co.kr. 무단 전재, 재배포 및 AI학습 이용 금지
- Samsung SDI Q4 OP second-best, annual record sales, eyes 80% jump in EV battery - Pulse by Maeil Business News Korea
- Hyundai Mobis OP up 17% in Q4 and down 22% for ’20, raises capex by 17% - Pulse by Maeil Business News Korea
- IMF thinks it’s right to bring back short sale to Korean stock markets - Pulse by Maeil Business News Korea
- SK Global Chemical partners with U.S. firm on plastic recycling technology - Pulse by Maeil Business News Korea
- S. Korea seeks to extend healthy life expectancy with higher tobacco, liquor prices - Pulse by Maeil Business News Korea
- 강경준, 상간남 피소…사랑꾼 이미지 타격 [MK픽] - 스타투데이
- 금융당국이 손보려는 농협중앙회...NH농협금융 지배구조 ‘복마전’ 왜?
- 백아연, 결혼 8개월만에 엄마 된다…“임신 5개월” - MK스포츠
- 이찬원, 이태원 참사에 "노래 못해요" 했다가 봉변 당했다 - 스타투데이
- 양희은·양희경 자매, 오늘(4일) 모친상 - 스타투데이